JP2020524993A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524993A5
JP2020524993A5 JP2019568601A JP2019568601A JP2020524993A5 JP 2020524993 A5 JP2020524993 A5 JP 2020524993A5 JP 2019568601 A JP2019568601 A JP 2019568601A JP 2019568601 A JP2019568601 A JP 2019568601A JP 2020524993 A5 JP2020524993 A5 JP 2020524993A5
Authority
JP
Japan
Prior art keywords
synthetic
cron
existent
nucleic acid
orf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019568601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524993A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037379 external-priority patent/WO2018232017A1/en
Publication of JP2020524993A publication Critical patent/JP2020524993A/ja
Publication of JP2020524993A5 publication Critical patent/JP2020524993A5/ja
Priority to JP2022187239A priority Critical patent/JP2023010961A/ja
Priority to JP2024069618A priority patent/JP2024087003A/ja
Withdrawn legal-status Critical Current

Links

JP2019568601A 2017-06-13 2018-06-13 クロンを含む組成物及びその使用 Withdrawn JP2020524993A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022187239A JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762518898P 2017-06-13 2017-06-13
US62/518,898 2017-06-13
US201762597387P 2017-12-11 2017-12-11
US62/597,387 2017-12-11
US201862676730P 2018-05-25 2018-05-25
US62/676,730 2018-05-25
PCT/US2018/037379 WO2018232017A1 (en) 2017-06-13 2018-06-13 Compositions comprising curons and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022187239A Division JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2020524993A JP2020524993A (ja) 2020-08-27
JP2020524993A5 true JP2020524993A5 (cg-RX-API-DMAC7.html) 2021-07-26

Family

ID=62846247

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019568601A Withdrawn JP2020524993A (ja) 2017-06-13 2018-06-13 クロンを含む組成物及びその使用
JP2022187239A Withdrawn JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A Pending JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022187239A Withdrawn JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A Pending JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Country Status (11)

Country Link
US (4) US20200123203A1 (cg-RX-API-DMAC7.html)
EP (1) EP3638797A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020524993A (cg-RX-API-DMAC7.html)
KR (2) KR20200038236A (cg-RX-API-DMAC7.html)
CN (1) CN111108208A (cg-RX-API-DMAC7.html)
AU (2) AU2018285860A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019026226A2 (cg-RX-API-DMAC7.html)
CA (1) CA3066750A1 (cg-RX-API-DMAC7.html)
IL (1) IL271275A (cg-RX-API-DMAC7.html)
MX (2) MX2019015018A (cg-RX-API-DMAC7.html)
WO (1) WO2018232017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2020123773A2 (en) * 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering secreted therapeutic modalities
KR20210131308A (ko) * 2018-12-12 2021-11-02 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포내 치료 양식을 운반하기 위한 아넬로좀
US20220042042A1 (en) * 2018-12-12 2022-02-10 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
BR112021010925A2 (pt) * 2018-12-12 2021-08-31 Flagship Pioneering Innovations V, Inc Anelossomos para entrega de modalidades terapêuticas de substituição de proteína
CA3143327A1 (en) 2019-06-13 2020-12-17 J. Keith Joung Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP3999642A1 (en) 2019-07-19 2022-05-25 Flagship Pioneering Innovations VI, LLC Recombinase compositions and methods of use
CN116075591A (zh) * 2020-06-12 2023-05-05 旗舰先锋创新V股份有限公司 串联型指环病毒构建体
EP4164667A4 (en) * 2020-06-12 2024-10-23 Flagship Pioneering Innovations V, Inc. Baculovirus expression systems
JP2023530451A (ja) * 2020-06-17 2023-07-18 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド アネロウイルスを同定し及び特徴付ける方法並びにその使用
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
US12018254B2 (en) * 2020-07-27 2024-06-25 Wisconsin Alumni Research Foundation Methods of making unbiased phage libraries
IL303892A (en) * 2020-12-23 2023-08-01 Flagship Pioneering Innovations V Inc In vitro assembly of RNA-encapsulating enalavirus capsids
CN117279669A (zh) * 2021-02-08 2023-12-22 旗舰先锋创新V股份有限公司 杂合aav-指环载体
US20250027107A1 (en) * 2021-10-18 2025-01-23 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR751473A (fr) * 1932-06-01 1933-09-04 Poste d'incendie
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
JP4951338B2 (ja) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉ｒｎａ
JP4842821B2 (ja) 2003-09-15 2011-12-21 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
EP2514758B2 (en) 2004-03-15 2021-06-23 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CA2571899A1 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
WO2007048046A2 (en) 2005-10-20 2007-04-26 Protiva Biotherapeutics, Inc. Sirna silencing of filovirus gene expression
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
JP5475753B2 (ja) 2008-04-15 2014-04-16 プロチバ バイオセラピューティクス インコーポレイティッド 核酸送達用の脂質製剤
US20100184841A1 (en) 2008-12-18 2010-07-22 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8603966B2 (en) 2009-02-27 2013-12-10 The Administrators Of The Tulane Educational Fund Amino acid-based compounds, their methods of use, and methods of screening
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2449106B1 (en) 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
US9676828B2 (en) * 2010-06-23 2017-06-13 Deutsches Krebsforschungszentrum Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
SG194099A1 (en) * 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
GB2537000C (en) 2012-05-25 2019-10-09 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
EP4556564A3 (en) 2012-10-23 2025-09-03 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
PL2771468T3 (pl) 2012-12-12 2015-07-31 Broad Inst Inc Inżynieria systemów, metod i zoptymalizowanych kompozycji kierujących dla manipulacji sekwencjami
US20140186919A1 (en) 2012-12-12 2014-07-03 Feng Zhang Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
KR20150105635A (ko) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2015089419A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Similar Documents

Publication Publication Date Title
JP2020524993A5 (cg-RX-API-DMAC7.html)
US11446344B1 (en) Anellovirus compositions and methods of use
JP2022037134A (ja) 単純ヘルペスウイルスワクチン
CN111108208A (zh) 包含愈合子的组合物及其用途
US20060188490A1 (en) Transfection of blood cells with mRNA for immune stimulation and gene therapy
JP2022512395A (ja) 分泌治療モダリティを送達するためのアネロソーム
JP2007511216A (ja) 変異ウイルス
US11931409B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
JP2019501661A5 (cg-RX-API-DMAC7.html)
CN110393791B (zh) hnRNPA2B1的抗感染作用及其应用
KR20210131310A (ko) 아넬로좀 및 사용 방법
JP2022513459A (ja) タンパク質代替治療モダリティを送達するためのアネロソーム
WO2019080537A1 (zh) 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
JP2022514501A (ja) 細胞内治療モダリティを送達するためのアネロソーム
WO2021253733A1 (en) Construct and use thereof
CN119736261A (zh) 溶瘤病毒及其应用
JP7047238B2 (ja) 安全性及び抗がん効果が改善した腫瘍溶解性ウイルス
CN111041001B (zh) 治疗kras突变型肿瘤的安全型柯萨奇病毒及其药物组合物
US11524047B2 (en) Pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer including CHI3L1 inhibitor as active ingredient
Ni et al. Antitumor efficacy of CRISPR/Cas9–engineered ICP6 mutant herpes simplex viruses in a mouse xenograft model for lung adenocarcinoma
EP1731599A1 (en) Method of constructing recombinant herpes simplex virus
JPWO2020123816A5 (cg-RX-API-DMAC7.html)
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
US20240050580A1 (en) Compositions targeting tumor associated macrophages and methods using same
CN114096661B (zh) 改进了安全性及抗肿瘤效果的溶瘤病毒